Quick Answer
Voyager Therapeutics, Inc. reported Net Income Loss of -$119.72 million for the year ending 2025.
- Voyager Therapeutics, Inc. showed a decrease of -84.2% in Net Income Loss from 2024 to 2025.
- This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: -$4.01 million | Q1 2015: -$14.58 million | Q2 2015: -$3.90 million | Q3 2015: -$3.92 million | Q1 2016: -$7.19 million | Q2 2016: -$9.34 million | Q3 2016: -$9.00 million | Q1 2017: -$16.65 million | Q2 2017: -$18.88 million | Q3 2017: -$23.35 million | Q4 2017: -$11.83 million | Q1 2018: -$19.93 million | Q2 2018: -$25.54 million | Q3 2018: -$20.29 million | Q4 2018: -$22.53 million | Q1 2019: -$27.17 million | Q2 2019: $11.15 million | Q3 2019: -$15.01 million | Q4 2019: -$12.57 million | Q1 2020: -$24.26 million | Q2 2020: -$8.68 million | Q3 2020: $85.61 million | Q1 2021: -$21.65 million | Q2 2021: -$30.12 million | Q3 2021: -$25.14 million | Q1 2022: -$21.32 million | Q2 2022: -$19.09 million | Q3 2022: $17.62 million | Q1 2023: $124.04 million | Q2 2023: -$22.21 million | Q3 2023: -$25.90 million | Q1 2024: -$11.33 million | Q2 2024: -$10.14 million | Q3 2024: -$9.04 million | Q1 2025: -$31.02 million | Q2 2025: -$33.38 million | Q3 2025: -$27.89 million.
- Over the full 12 years of available data (2014 to 2025), Voyager Therapeutics, Inc.'s Net Income Loss has declined by 633.7%.
- Historical annual values: Fiscal year 2025: -$119.72 million | Fiscal year 2024: -$65.00 million | Fiscal year 2023: $132.33 million | Fiscal year 2022: -$46.41 million | Fiscal year 2021: -$71.20 million | Fiscal year 2020: $36.74 million | Fiscal year 2019: -$43.60 million | Fiscal year 2018: -$88.29 million | Fiscal year 2017: -$70.70 million | Fiscal year 2016: -$40.19 million | Fiscal year 2015: -$29.67 million | Fiscal year 2014: -$16.32 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: